31 completed, 9 terminated, 3 unknown, 1 withdrawn. 24 Phase 2, 21 Phase 1, 8 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow oblimersen: new trials by email Literature Review of oblimersen trials Research Report on oblimersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma Genasense, Paclitaxel, Carboplatin - Melanoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2010-12-01 | 2016-02-11 |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Early Phase 1 | Terminated | University of Nebraska | 37 | 2008-07-23 | 2023-10-24 |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma dacarbazine plus Genasense, dacarbazine plus placebo - Melanoma | Phase 3 | Completed | Genta Incorporated | 300 | 2007-07-01 | 2011-11-07 |
| Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors Oblimersen (Genasense) - Solid Tumors | Phase 1 | Completed | Genta Incorporated | 25 | 2007-05-01 | 2012-04-06 |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide) - Melanoma | Phase 1 | Unknown | Genta Incorporated | 28 | 2006-11-01 | 2011-11-07 |
| This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia | Phase 3 | Withdrawn | Genta Incorporated | 2006-06-01 | 2008-02-11 | |
| Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function Genasense (oblimersen, G3139) - Normal Renal Function, Mildly Impaired Renal Function | Phase 1 | Completed | Genta Incorporated | 23 | 2006-05-01 | 2012-03-13 |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine Genasense® (G3139, oblimersen sodium), Genasense followed by DTIC; then DTIC alone, DTIC alone; then Genasense followed by DTIC - Advanced Melanoma | Phase 1 | Completed | Genta Incorporated | 2006-04-01 | 2012-03-13 | |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, laboratory biomarker analysis - Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 52 | 2006-03-01 | 2013-01-07 |
| A Phase I Study of G3139 Subcutaneous in Solid Tumors G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide - Tumors | Phase 1 | Completed | Genta Incorporated | 8 | 2005-12-01 | 2007-10-12 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery oblimersen sodium, imatinib mesylate, laboratory biomarker analysis - Gastrointestinal Stromal Tumor | Phase 2 | Terminated | National Cancer Institute (NCI) | 96 | 2005-09-01 | 2013-06-05 |
| Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment Genasense® (G3139, oblimersen sodium) - Advanced Melanoma and Normal or Impaired, Hepatic Function | Phase 2 / Phase 3 | Terminated | Genta Incorporated | 6 | 2005-08-01 | 2011-11-07 |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, ifosfamide - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2004-05-01 | 2013-01-24 |
| Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate oblimersen sodium, docetaxel - Prostate Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 116 | 2004-04-01 | 2012-09-24 |
| S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 160 | 2004-03-01 | 2013-01-07 |
| Oblimersen in Treating Patients With Merkel Cell Carcinoma oblimersen sodium, pharmacological study, laboratory biomarker analysis - Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2004-01-01 | 2013-06-04 |
| Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia oblimersen sodium, cytarabine, daunorubicin hydrochloride - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 3 | Completed | National Cancer Institute (NCI) | 500 | 2003-12-01 | 2026-06-01 |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer recombinant interferon alfa, oblimersen sodium, pharmacological study - Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2003-08-01 | 2013-08-26 |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 oblimersen sodium, dacarbazine - Melanoma (Skin) | Not applicable | Unknown | Jonsson Comprehensive Cancer Center | 2003-08-01 | 2014-01-06 | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Lymphoma | Phase 1 | Completed | British Columbia Cancer Agency | 2003-07-01 | 2009-04-07 |
Showing 20 of 44. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (6) · Melanoma (5) · Leukemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Follicular (4) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Lymphoma, Mantle-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Rectal Neoplasms (3) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2)
National Cancer Institute (NCI) (19) · Genta Incorporated (14) · The University of Texas Health Science Center at San Antonio (2) · British Columbia Cancer Agency (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · University Health Network, Toronto (1) · University of Chicago (1) · University of Maryland, Baltimore (1) · University of Nebraska (1)
United States (39) · Canada (4) · Austria (2) · France (2) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Israel (1) · Netherlands (1)
Stanley R. Frankel, MD (4) · Anthony W. Tolcher, MD (2) · Guido Marcucci (2) · Andreas Kaubisch (1) · Anna C Pavlick, MD (1) · Ashraf Z. Badros, MD (1) · Barbara Grant (1) · Barbara Pro (1) · Charles M. Rudin, MD, PhD (1) · Charles Rudin (1) · Cora N. Sternberg, MD, FACP (1) · Deborah Braccia (1) · Francisco Esteva (1) · George Wilding (1)
PMID 12056703, PMID 15867202, PMID 16186597, PMID 16730060, PMID 17296974, PMID 18060598, PMID 19297314, PMID 19373653, PMID 19738118, PMID 19738454, PMID 31171508, PMID 31375516, PMID 34251414, PMID 36184192
U10CA031946 (4), N01CM17003 (2), N01CM62202 (2), N01CM17101 (1), N01CM17102 (1), N01CM17104 (1), N01CM17107 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1), N01CM62206 (1), N01CM62207 (1), P30CA016672 (1), P30CA036727 (1), P30CA054174 (1)